GlobeNewswire

Oxford Immunotec Reports Fourth Quarter and Full Year 2017 Financial Results

Del
  • 2017 marks the 13th consecutive year of at least 20% year-over-year constant currency revenue growth
  • >25% pro forma organic growth for the year in tick-borne disease and other revenue
  • Balance sheet strengthened by December patent infringement settlement, which included a cash receipt of $27.5 million
  • Reduced royalty burden resulted in substantial gross margin improvement

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced fourth quarter and full year 2017 financial results.

"While the year contained many ups and downs, in aggregate I am pleased with the substantial progress made throughout the Company in 2017" said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "2017 highlights included stronger-than-expected performance in Asia, a marked acceleration in Europe & ROW revenue growth, outperformance of our clinical tick-borne disease business, and the successful culmination of several strategically important multi-year initiatives on intellectual property, royalties and reimbursement."

By revenue type, total revenues were, in millions:

    Three Months Ended December 31,   Full Year Ended December 31,
    2017   2016   Percent 
Change
  2017   2016   Percent 
Change
                         
Product   $   9.7   $   9.3   5%   $   40.5   $   36.4   11%
Service       15.3     14.4   6%     62.6     49.6   26%
Total Revenue   $   25.0   $   23.7   6%   $   103.1   $   86.1   20%
                         

By indication, total revenues were, in millions:

    Three Months Ended December 31,   Full Year Ended December 31,
     2017    2016   Percent 
Change
   2017    2016   Percent 
Change
                         
Tuberculosis   $   21.0   $   20.4   3%   $   85.3   $   78.6   9%
Tick-Borne Disease and Other       4.0      3.3   24%        17.8      7.4   139%
Total Revenue   $   25.0   $   23.7   6%   $    103.1   $   86.1   20%
                         

By geography, total revenues were, in millions:

    Three Months Ended December 31,   Full Year Ended December 31,
            Percent Change           Percent Change
    2017   2016   As 
Reported
  Constant 
Currency (1)
  2017   2016   As 
Reported
  Constant 
Currency (1)
                                 
United States   $   15.6   $   14.7   6%   6%   $   64.1   $   49.5   30%   30%
Europe & ROW       2.2       1.7   27%   21%       8.1       7.0   16%   17%
Asia       7.2       7.3   -1%   2%       30.9       29.6   4%   6%
Total Revenue   $   25.0   $   23.7   6%   6%   $ 103.1   $   86.1   20%   20%
                                 

(1) Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "constant currency basis" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. We consider the use of a period over period revenue comparison on a constant currency basis to be helpful to investors, as it provides a revenue growth measure free of positive or negative volatility due to currency fluctuations.

Fourth Quarter 2017 Financial Results

Revenue for the fourth quarter of 2017 was $25.0 million, representing 6% growth over the fourth quarter 2016 revenue of $23.7 million. Tuberculosis revenue for the fourth quarter of $21.0 million increased 3% over the prior year period. 

2017 fourth quarter product revenue was $9.7 million, representing a 5% increase from product revenue of $9.3 million in the fourth quarter of 2016. The increase in product revenue was primarily driven by strong growth in tuberculosis kit sales in Europe & ROW. Service revenue for the fourth quarter of 2017 was $15.3 million, up 6% from 2016 fourth quarter revenue of $14.4 million. The increase in service revenue was primarily driven by strong growth in our clinical tick-borne disease business, as well as tuberculosis volume increases in the United States and United Kingdom.

United States revenue was $15.6 million in the fourth quarter of 2017, representing 6% growth over revenue of $14.7 million in the prior year period. The increase was due to growth in our tuberculosis and tick-borne disease businesses.

Europe & ROW revenue was $2.2 million in the fourth quarter of 2017, representing a 27% increase compared to the fourth quarter of 2016. On a constant currency basis, Europe & ROW increased 21% versus the fourth quarter of 2016. The increase was primarily due to tuberculosis growth in the UK and continental European markets.

Asia revenue was $7.2 million in the fourth quarter of 2017, representing a 1% decrease compared to 2016 fourth quarter revenue of $7.3 million. On a constant currency basis, Asia grew 2% versus the fourth quarter of 2016.

Gross profit for the fourth quarter of 2017 was $14.5 million, an increase of $1.9 million over gross profit of $12.5 million in the same period of 2016. Gross margin for the fourth quarter of 2017 was 57.7%, an increase of 490 basis points from gross margin of 52.8% in the fourth quarter of 2016. The increase in gross margin was primarily the result of lower royalty expenses and favorable product mix.

Operating expenses were $28.1 million in the fourth quarter of 2017, an increase of $8.4 million compared to $19.7 million in the same period last year. The increase in operating expenses was largely due to the inclusion of a one-time non-cash impairment charge of $7.2 million to write-off certain intangible assets acquired in conjunction with the 2016 acquisition of Immunetics, as well as expenses related to our BLA submissions and patent litigation.

Net income for the fourth quarter of 2017 was $8.8 million, or $0.33 per share on a diluted basis, compared to a net loss $4.9 million, or $0.22 per share in the fourth quarter of 2016. Diluted net loss per share was based on 26,828,912 and 22,412,691 weighted average ordinary shares outstanding for the fourth quarters of 2017 and 2016, respectively. 

EBITDA for the fourth quarter of 2017 was $14.4 million compared to $(6.9) million in the fourth quarter of 2016. Adjusted EBITDA was $(4.0) million for the fourth quarter compared to $(5.2) million in the same period in 2016. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Full Year 2017 Financial Results

Revenue for the full year 2017 was $103.1 million, representing 20% growth over the full year 2016 revenue of $86.1 million.

2017 full year product revenue was $40.5 million representing an 11% increase from product revenue of $36.4 million in the full year 2016. The increase in product revenue was primarily driven by growth in TB volumes in Asia and Europe & ROW, as well as sales of tick-borne disease kits. Service revenue for the full year 2017 was $62.6 million, up 26% from $49.6 million in the full year 2016. The increase in service revenue was primarily driven by revenues from our tick-borne disease business, as well as tuberculosis volume increases in the United States and United Kingdom.

United States revenue was $64.1 million in the full year 2017 representing 30% growth compared to full year 2016 revenue of $49.5 million. The increase in United States revenue was primarily due to revenues from our tick-borne disease business.

Europe & ROW revenue was $8.1 million in the full year 2017 representing a 16% increase compared to full year 2016 revenue of $7.0 million. On a constant currency basis, Europe & ROW grew 17% versus the full year 2016. Asia revenue was $30.9 million in the full year 2017 representing 4% growth over full year 2016 revenue of $29.6 million. On a constant currency basis, Asia grew 6% versus the full year 2016. The increase was driven by continued growth in China and higher sales in South Korea.

Gross profit for the full year 2017 was $56.3 million, an increase of $9.7 million over gross profit of $46.6 million in the full year 2016. Gross margin was 54.7%, an increase of 60 basis points from a gross margin of 54.1% in the full year 2016. The full year gross margin performance reflects lower royalty expenses and an underlying improvement in tuberculosis cost of revenues. These margin benefits were partially offset by higher volumes in our tick-borne disease business, which carries lower gross margins, as well as some early infrastructure investments necessary to meet future growth.

Operating expenses were $109.9 million in the full year 2016, an increase of $37.4 million compared to $72.6 million in the full year 2016. The increase in operating expenses was due to the inclusion of a full year of operating costs from both Imugen and Immunetics, expenses related to our BLA submissions and patent litigation, the inclusion of a charge related to the SSI settlement, and the inclusion of non-cash impairment charges of $18.3 million to write-off certain intangible assets acquired in conjunction with the 2016 acquisitions of Imugen and Immunetics.

Net loss for the full year 2017 was $32.9 million, or $1.38 per share, compared to a loss of $22.3 million, or $1.00 per share for the full year 2016. Net loss per share was based on 23,757,902 and 22,353,713 weighted average ordinary shares outstanding for the full years 2017 and 2016, respectively. 

EBITDA for the full year 2017 was $(23.9) million compared to $(22.2) million for the full year 2016. Adjusted EBITDA was $(20.0) million for the full year 2017 compared to $(18.5) million for the full year 2016. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Cash and cash equivalents were $90.3 million as of December 31, 2017. This compares to cash and cash equivalents of $59.1 million as of December 31, 2016.

Business Outlook

For full year 2018, the Company expects revenue of between $112 and $118 million, representing 9% - 15% year-over-year growth as reported.

Conference Call

Oxford Immunotec will host a conference call on Tuesday, February 27, 2018 at 8:00 a.m. Eastern Time to review fourth quarter and full year 2017 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 6949857, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com.  The replay will be available on the Company's website for approximately 60 days.  

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions.  The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.  Immunetics is a trademark of Immunetics, Inc.

This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACT:

For Media and Investor Inquiries: 
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com

Oxford Immunotec Global PLC
Condensed consolidated statements of operations
(unaudited)

    Three months ended December 31,   Year ended December 31,
(in thousands, except share and per share data)   2017   2016   2017   2016
Revenue                
Product   $   9,714      $   9,286      $   40,522      $   36,430   
Service       15,312          14,419          62,558          49,648   
Total revenue       25,026          23,705          103,080          86,078   
Cost of revenue                
Product       2,428          3,535          13,794          13,956   
Service       8,146          7,663          32,937          25,516   
Total cost of revenue       10,574          11,198          46,731          39,472   
Gross profit       14,452          12,507        56,349          46,606   
Operating expenses:                
Research and development       4,481          4,044          16,701          13,881   
Sales and marketing       8,842          8,299          38,016          34,964   
General and administrative       7,359          6,981          30,366          23,181   
Change in fair value of contingent purchase price consideration       -          (1,380 )       (3,475 )       (1,208 )
Intangible assets impairment charges       7,236          1,765          18,300          1,765   
Settlement expense       197          -          10,028          -   
Total operating expenses       28,115          19,709          109,936          72,583   
Loss from operations       (13,663 )       (7,202 )       (53,587 )       (25,977 )
Other income (expense):                
Interest expense, net       (694 )       (776 )       (3,105 )       (864 )
Foreign exchange (losses) gains       (573 )       (343 )       (1,850 )       1,364   
Other income (expense)       53          (403 )       (209 )       (646 )
Litigation settlement income       27,500          -          27,500          -   
Income (loss) before income taxes       12,623          (8,724 )       (31,251 )       (26,123 )
Income tax (expense) benefit       (3,823 )       3,866          (1,634 )       3,774   
Net income (loss)    $   8,800      $   (4,858 )   $   (32,885 )   $   (22,349 )
                 
Net income (loss) per ordinary share:                
Basic   $   0.34     $   (0.22 )   $   (1.38 )   $   (1.00 )
Diluted   $   0.33     $   (0.22 )   $   (1.38 )   $   (1.00 )
                 
Weighted-average shares used to compute net income (loss) per ordinary share:                
Basic       25,532,152          22,412,691          23,757,902          22,353,713   
Diluted       26,828,912          22,412,691          23,757,902          22,353,713   
                 

Reconciliation of net loss to Adjusted EBITDA (1)
(unaudited)

    Three months ended December 31,   Year ended December 31,
(in thousands)   2017   2016   2017   2016
Net loss   $   8,800      $   (4,858 )   $   (32,885 )   $   (22,349 )
Income tax (benefit) expense       3,823          (3,866 )       1,634          (3,774 )
Interest expense, net       553          776         2,535          864   
Depreciation and amortization       1,125          1,027          4,240          3,094   
Accretion and amortization of loan fees       141          -          570          -   
EBITDA       14,442          (6,921 )     (23,906 )       (22,165 )
                 
Reconciling items:                
Share-based compensation expense       1,598          1,192          5,864          5,019   
Unrealized exchange (gains) losses       72          110          686          (1,880 )
Change in fair value of contingent purchase price consideration       -          (1,380 )       (3,475 )       (1,208 )
Intangible asset impairment charge       7,236          1,765          18,300          1,765   
Settlement expense       197          -          10,028          -   
Litigation settlement income       (27,500 )       -          (27,500 )       -   
Adjusted EBITDA   $   (3,955 )   $   (5,234 )   $   (20,003 )   $   (18,469 )
                 

(1)  EBITDA and Adjusted EBITDA are non-GAAP measures that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that these measures provide useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of these measures is not made in accordance with U.S. GAAP, and our computation of these measures may vary from others in the industry. Our use of these measures has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.

The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.

Oxford Immunotec Global PLC
Condensed consolidated balance sheets
(unaudited)

    December 31,
(in thousands, except share and per share data)   2017   2016
Assets        
Current assets:        
Cash and cash equivalents   $   90,332      $   59,110   
Accounts receivable, net       16,981          13,265   
Inventory, net       10,142          7,437   
Prepaid expenses and other assets       3,027          2,390   
Total current assets       120,482          82,202   
Restricted cash, non-current       200          200   
Property and equipment, net       9,067          7,793   
In-process research and development       -          16,170   
Goodwill       3,967          3,822   
Other intangible assets, net       7,849          11,017   
Deferred tax asset       2,486          2,630   
Other assets       185          178   
Total assets   $   144,236      $   124,012   
         
Liabilities and shareholders' equity        
Current liabilities:        
Accounts payable   $   6,842      $   3,201   
Accrued liabilities       11,134          14,282   
Settlement liability       4,342          -   
Contingent purchase price consideration       -          882   
Deferred income       36          41   
Current portion of loans payable       91          84   
Total current liabilities       22,445          18,490   
Long-term portion of loans payable       29,904          29,601   
Settlement liability       3,894          -   
Contingent purchase price consideration       -          2,593   
Other liabilities       364          364   
Total liabilities       56,607          51,048   
         
Shareholders' equity:        
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at December 31, 
2017 and December 31, 2016, and 25,661,634 and 22,635,431 shares issued and 
outstanding at December 31, 2017 and 2016, respectively
      269          243   
Additional paid-in capital       294,613          249,128   
Accumulated deficit       (201,541 )       (168,656 )
Accumulated other comprehensive loss       (5,712 )       (7,751 )
Total shareholders' equity       87,629          72,964   
Total liabilities and shareholders' equity   $   144,236      $   124,012   
         



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Compuware Announces Day One Support for IBM CICS Transaction Server for z/OS V5.514.12.2018 18:02Pressemelding

DETROIT, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Compuware Corporation, the world’s leading mainframe-dedicated software company, is pleased to announce Day One support for IBM CICS Transaction Server (TS) for z/OS V5.5. Compuware worked in collaboration with IBM to ensure that its solutions—including Abend-AID, File-AID, Strobe, Topaz and Xpediter—work seamlessly for z/OS customers installing or upgrading to this newest version of CICS TS. New capabilities within CICS TS V5.5 include support for JavaScript Node.js applications; an enhanced CICS Explorer; as well as advancements in systems management and enhanced security. “Compuware has an extensive history of ensuring our products work seamlessly with IBM releases and the release of CICS Transaction Server V5.5 is no exception,” said Sam Knutson, Vice President of Product Management for Compuware. “Our solutions excel at helping enterprises include the mainframe in their cross-platform Agile DevOps practices and processes so they can succe

SoftServe Achieves Machine Learning Specialization in Google Cloud Partner Program14.12.2018 13:00Pressemelding

Google Cloud recognizes SoftServe’s technical proficiency and proven success AUSTIN, Texas, Dec. 14, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it achieved the Machine Learning Partner Specialization in the Google Cloud Premier Partner Program. The Partner Specialization affirms SoftServe’s expertise and success building customer solutions in the machine learning field using Google Cloud Platform (GCP) technology. The Google Cloud Partner Specialization Program is designed to provide Google Cloud customers with qualified partners that demonstrate technical proficiency in the specialized solution and service areas. Specifically, the Machine Learning Specialization demonstrates SoftServe’s expertise in data exploration, preprocessing, model training, model evaluation, model deployment, online prediction, and Google Cloud’s pre-trained machine learning APIs. “We teach machines to learn, read, see and understand business data, and make

Minerals Technologies Announces Price Increases for Specialty Minerals Products in Europe14.12.2018 00:01Pressemelding

NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Specialty Minerals Inc. (“SMI”), a subsidiary of Minerals Technologies Inc., announced today that effective February 1, 2019, it will increase prices by up to 10% for all coated ultrafine precipitated calcium carbonate (PCC) from SMI’s Lifford Specialty PCC facility in Birmingham, UK, subject to individual customer contracts and market provisions. The price increases reflect increased market demand for higher performance materials, as well as significant inflation in input, raw material and logistics costs. About Minerals Technologies Inc. New York-based Minerals Technologies Inc. (MTI) is a resource- and technology-based growth company that develops, produces and markets worldwide a broad range of specialty mineral, mineral-based and synthetic mineral products and related systems and services. MTI serves the paper, foundry, steel, construction, environmental, energy, polymer and consumer products industries. The Company reported sales of $1.

Synthesio to Bring Proven Ipsos Data Science to Artificial Intelligence13.12.2018 17:03Pressemelding

Synthesio's Next-Generation Social Media Intelligence to Raise Unseen Insights to the Surface, Faster NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Synthesio, an Ipsos company, and also the leading Social Media Intelligence Suite, today announced the plans for its next-generation Artificial Intelligence (AI) engine. The project will combine Synthesio’s AI technology with Ipsos’ data science. The combination will power upcoming Synthesio capabilities to help users find insights faster, remove guesswork, and make informed business decisions across a variety of use cases. “Our goal has always been to provide customers with meaningful data, visualized so that they can make strategic business decisions,” explained Loic Moisand, CEO & Founder of Synthesio. “The less guesswork that a company has to make, and the less time that it takes users to find meaningful insights, the more time for data-backed business decisions. We are really pleased that we can leverage the data science capabilities dev

XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study13.12.2018 14:00Pressemelding

Biomarkers Predict Significantly Higher Rates of Treatment Response to Bermekimab in Advanced Cancer Patients AUSTIN, Texas, Dec. 13, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the publication of findings on key biomarker analysis of colorectal cancer patients treated with bermekimab in its European Phase III study. The manuscript, entitled, “Interleukin-1 Receptor Antagonist (IL-1ra) Levels Predict Favorable Outcome after Bermekimab, a First-in-Class True Human Interleukin-1α Antibody, in a Phase III Randomized Study of Advanced Colorectal Cancer”, has been published online in the journal OncoImmunology. The findings report that patients with relatively low levels of IL-1ra or IL-6 were more likely to respond to bermekimab therapy and achieve the study’s primary endpoint. The study’s primary endpoint measured a combination of physical symptoms—pain, fatigue, anorexia and muscle wasting—which tend to worsen with advanced cancer, to assess whether these sympto

FROM CUTE TO CONFIDENT: MARY KAY INC. TALKS PINK AT THE MUSEUM AT FIT13.12.2018 14:00Pressemelding

Mary Kay Inc. and The Museum at The Fashion Institute of Technology Partner for a Pink-Centric Panel Discussion in Conjunction with Special Exhibition ‘Pink: The History of a Punk, Pretty, Powerful Color’ NEW YORK, N.Y., Dec. 13, 2018 (GLOBE NEWSWIRE) -- From pink makeup compacts to the iconic pink Cadillac, global beauty brand Mary Kay has been synonymous with the color pink for more than five decades. On December 13, 2018, Mary Kay will partner with The Museum at FIT (MFIT) to host a scholarly panel discussion, ‘Powerful Pink: From Cute to Confident,’ at the Katie Murphy Amphitheatre on the New York City FIT campus. Panelists include Luis Casco, Mary Kay Global Beauty Ambassador and celebrity makeup artist; Kate Greene, Vice President of Communications and Creative Direction at Givaudan and Karen Young, FIT adjunct professor and founder of The Young Group. The panel discussion will be moderated by Sheryl Adkins-Green, Chief Marketing Officer for Mary Kay Inc. The scholarly panel disc